AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
ARTHEx Biotech has raised $40.6M in total funding. The most recent round was Series B. The last funding was announced in September 2025.
ARTHEx Biotech's investors include Bpifrance, European Innovation Council, Columbus Venture Partners, Sound Bioventures, Hadean Ventures.
ARTHEx Biotech is headquartered in Valencia, Spain.
AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
ARTHEx Biotech is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ARTHEx Biotech — Funding & Investors." VCBacked, September 17, 2025, https://www.vcbacked.co/company/arthex-biotech. Accessed September 3, 2026.
VCBacked. (2025). ARTHEx Biotech — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/arthex-biotech
{{cite web |title=ARTHEx Biotech — Funding & Investors |url=https://www.vcbacked.co/company/arthex-biotech |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated